People s United Financial Inc. decreased its stake in Pfizer Inc. (NYSE:PFE) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 601,909 shares of the biopharmaceutical company’s stock after selling 16,999 shares during the period. People s United Financial Inc.’s holdings in Pfizer were worth $21,837,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in PFE. BlackRock Inc. raised its position in Pfizer by 1.5% in the first quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock worth $16,308,754,000 after acquiring an additional 6,785,335 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Pfizer by 11.9% in the first quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after purchasing an additional 4,998,981 shares in the last quarter. Jensen Investment Management Inc. purchased a new position in shares of Pfizer in the second quarter worth about $110,291,000. Robeco Institutional Asset Management B.V. increased its stake in shares of Pfizer by 75.3% in the first quarter. Robeco Institutional Asset Management B.V. now owns 7,038,854 shares of the biopharmaceutical company’s stock worth $249,807,000 after purchasing an additional 3,024,270 shares in the last quarter. Finally, Neuberger Berman Group LLC increased its stake in shares of Pfizer by 17.9% in the first quarter. Neuberger Berman Group LLC now owns 16,056,110 shares of the biopharmaceutical company’s stock worth $569,979,000 after purchasing an additional 2,432,694 shares in the last quarter. 69.01% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently weighed in on the stock. Goldman Sachs Group reiterated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research note on Tuesday, August 28th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Independent Research set a $48.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Credit Suisse Group lifted their target price on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. Finally, Barclays reiterated a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a research note on Wednesday, September 26th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $42.95.
In other news, major shareholder Pfizer Inc acquired 55,556 shares of Pfizer stock in a transaction that occurred on Monday, October 15th. The stock was bought at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.
Shares of NYSE:PFE opened at $42.93 on Friday. The company has a market cap of $255.56 billion, a P/E ratio of 14.41, a PEG ratio of 2.16 and a beta of 0.88. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. Pfizer’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 3 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 3.17%. Pfizer’s dividend payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.